Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function

Sakabe, Koichi; Fukuda, Nobuo; Fukuda, Yamato; Wakayama, Katsunori; Nada, Teru; Morishita, Satofumi; Shinohara, Hisanori; Tamura, Yoshiyuki

doi:10.1016/j.ijcard.2007.01.040

Cited by 35 publications

(38 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Third, the concentration of atorvastatin required to promote vascular smooth muscle growth or inhibit migration in vitro is 1,000 nmol/L, 28 while that of pitavastatin is as low as 10 nmol/L. 30 These findings suggest that the direct pleiotropic effect of pitavastatin on vascular wall plaques is stronger than that of atorvastatin and that transfer of pitavastatin to blood vessels is more efficient. Therefore, a sufficient concentration of pitavastatin might be present to maintain the pleiotropic effect, leading to rapid manifestation of the pharmacological activity of pitavastatin.…”

Section: Discussionmentioning

confidence: 96%

Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin

Toi

Tanaka

Yoneda

et al. 2009

Circ J

View full text Add to dashboard Cite

arge-scale clinical studies have recently shown an inhibitory effect on cardiovascular events of lipidlowering therapy with HMG-CoA reductase inhibitors (statins), indicating the usefulness of this therapy. [1][2][3][4][5][6][7][8] The benefit is particularly marked in patients with coronary heart disease (CHD), and the guidelines of the American National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III positively state the utility of lipid-lowering therapy in reducing low-density lipoprotein (LDL)-cholesterol (C) to below 70 mg/dl in patients with coronary artery disease. 9 In Japan, the guidelines for prevention of arteriosclerotic diseases specify a target value of LDL-C of less than 100 mg/dl for control of CHD patients in category C. 10 Evaluation of coronary arterial plaques by imaging diagnosis has progressed markedly in recent years. In the REVERSAL study, intravascular ultrasonography (IVUS) was used to compare the effect of lipid-lowering therapy between CHD patients treated with standard and active regimens, with the latter found to inhibit expansion of coronary plaques. 11 Size reduction of coronary plaques on IVUS by statin treatment in patients with acute coronary syndrome (ACS) has also been reported in Japan (the ESTABLISH study). 12 Subsequent multicenter studies such as the JAPAN-ACS study have verified the ESTABLISH results through investigation of strong statin-induced volume reduction of coronary plaques. [13][14][15] However, these studies have all evaluated quantitative changes of the plaques, and there have been fewer qualitative evaluations. 16 Spectral analysis of IVUS radiofrequency (RF) data can provide detailed quantitative and qualitative information on coronary plaque composition in vivo. [17][18][19][20][21] Nasu et al found that in vivo characterization of coronary plaques by 'virtual histology (VH)' correlated favorably with the results of in vitro histopathological examination of tissue samples obtained by directional coronary atherectomy. 22 In this study, we used VH-IVUS to evaluate short-term quantitative and qualitative changes in non-culprit lesions in a comparison of pitavastatin, a new strong statin, with atorvastatin after administration in the early stage (2-3 weeks) after onset of ACS. The follow-up period of 2-3 weeks was chosen to evaluate the inhibition of short-term events within 1 month by early statin administration after ACS onset, and to examine if the statin effect starts to appear in this period. Methods Study Design and Patient PopulationThe study was performed as a prospective, randomized, single-center trial to assess the effect of 2-to 3-weeks of (Received November 5, 2008 Patients with acute coronary syndrome who underwent emergency percutaneous coronary intervention (PCI) were randomly assigned to receive pitavastatin (n=80; 2 mg/day) or atorvastatin (n=80; 10 mg/day) immediately after PCI. All patients underwent a blood lipid test and VH-IVUS evaluation of non-PCI lesions at admission and after 2-3 weeks of statin administration. A...

show abstract

Section: Discussionmentioning

confidence: 96%

Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin

Toi

Tanaka

Yoneda

et al. 2009

Circ J

View full text Add to dashboard Cite

show abstract

“…[7][8][9] Statins reduce cardiovascular events in dyslipidemic patients for both primary 10,11 and secondary prevention 12 of coronary arterial events by lowering of lipid levels, including the oxidized low-density lipoprotein-cholesterol (LDL-C) involved in atherosclerosis, and via pleiotropic effects, because mevalonate is a precursor of various nonsteroidal isoprenoid products as well as cholesterol. Effects of strong statins on postprandial endothelial function, blood rheology and adiponectin in patients with dyslipidemia or DM have been reported, [13][14][15][16] but effects in patients with coronary artery disease (CAD) are not fully understood. 17 Such information might be valuable in constructing better therapeutic strategies for patients with CAD.…”

mentioning

confidence: 99%

Effects of Pitavastatin on Fasting and Postprandial Endothelial Function and Blood Rheology in Patients With Stable Coronary Artery Disease

Arao

Yasu

Umemoto

et al. 2009

Circ J

View full text Add to dashboard Cite

show abstract

“…In two cases, pitavastatin was suggested to improve not only LDL-C and HDL-C, but also HOMA-IR and GIR. Pitavastatin has pleiotropic effects which do not depend on lipid diminishing actions such as the anti-inflammatory effect [9], antioxidant effect [10] and endothelial function improvement [11]. In addition, it has been confirmed that pitavastatin increases adiponectin in hypercholesterolemic and patients with type 2 diabetes [12], and these actions may contribute to the amelioration of insulin resistance.…”

Section: Discussionmentioning

confidence: 97%

Pitavastatin Ameliorates Insulin Resistance in Type 2 Diabetic Patients: Report of Two Cases

Satoh¹,

Kudoh²,

Hikita³

et al. 2012

J Diabetes Metab

View full text Add to dashboard Cite

Introduction: Statins reduce cardiovascular risk in populations targeted for both primary and secondary prevention. The potential of statin use to impact the risk of developing new onset diabetes has been suggested. However, there have been a few large-scale RCTs of pitavastatin which is the statin, but adverse effects on glucose metabolism and diabetes onset were not documented by meta analysis.Case reports: We report two patients with type 2 diabetes and hypercholesterolemia showing amelioration of insulin resistance with pitavastatin. The improvements were attributed to effects of pitavastatin on glucose and insulin metabolism. A 75-year-old man and a 70-year-old woman with type 2 diabetes, hypercholesterolemia and hypertension were given pitavastatin (2 mg/day) for 6 months, without changes in other medication. Before and after treatment, both received euglycemic hyperinsulinemic clamp studies to assess insulin sensitivity. After 6 months, glucose infusion rates were increased in both subjects. Conclusion:These cases suggest that pitavastatin, unlike other statins, has beneficial effects on insulin sensitivity in an insulin-resistant state.

show abstract

Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function

Cited by 35 publications

References 6 publications

Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin

Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque Comparison With Atorvastatin

Effects of Pitavastatin on Fasting and Postprandial Endothelial Function and Blood Rheology in Patients With Stable Coronary Artery Disease

Pitavastatin Ameliorates Insulin Resistance in Type 2 Diabetic Patients: Report of Two Cases

Contact Info

Product

Resources

About